Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 4 (A) Comparison of glycoprotein IIb/IIIa receptor inhibition trials in patients testing troponin-positive demonstrates marked homogeneity. p < 0.001 Breslow-Day homogeneity. (B) Clinical outcomes at 14 days for patients treated with enoxaparin versus unfractionated heparin (UFH) stratified by 0 to 24 h cardiac troponin I (cTnl) results. CI = confidence interval; CKMB Neg. Pts = creatine kinase-myocardial band-negative patients; D/MI/UR = death, MI, or urgent revascularization; GUSTO = Global Use of Strategies To Open occluded arteries in acute coronary syndromes trial; IIb/IIIa = glycoprotein IIb/IIIa receptor inhibitor; PARAGON = Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome Global Organization trial; PRISM = Platelet Receptor Inhibition for Ischemic Syndrome Management trial; RR = relative risk of the outcome for patients treated with enoxaparin versus unfractionated heparin. Reprinted with permission from the American College of Cardiology (J Am Coll Cardiol 2000;36:1812–7).
